Phospholipid transfer protein (PLTP) (PLTP)

Phospholipid transfer protein (PLTP) is a secreted glycoprotein belonging to the BPI/LBP/PLTP family, primarily responsible for the transfer of phospholipids between lipoprotein particles [1]. It plays a crucial role in the remodeling of high-density lipoproteins (HDL), facilitating the transfer of phospholipids from triglyceride-rich lipoproteins like VLDL to HDL, and mediating the conversion of HDL into larger and smaller (pre-beta) particles [2]. PLTP is considered a significant therapeutic target because its activity is positively correlated with the development of atherosclerosis and cardiovascular disease in humans [3]. Elevated PLTP levels are also observed in metabolic conditions such as obesity and type 2 diabetes, where it contributes to dyslipidemia [4]. While no PLTP-targeted drugs are currently FDA-approved, experimental small-molecule inhibitors have been developed and tested in animal models, showing promise in reducing atherosclerotic plaque progression [5]. However, therapeutic development is challenged by PLTP's dual role, as it also participates in the innate immune response by binding and neutralizing bacterial lipopolysaccharides [6].

Other names

Lipid transfer protein IIPhospholipid transfer proteinPhospholipid carrier protein

Inhibition of phospholipid transfer activity to modulate HDL remodeling and reduce pro-atherogenic lipoprotein levels.